High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome.

Despite high sensitivity to chemotherapy, the prognosis for triple-negative breast cancer (TNBC) remains poor because of its high rate of metastasis and low sensitivity to endocrine therapy. CXCR4 expression has been reported in many subtypes of human breast cancers, but it remains unknown whether CXCR4 is expressed in TNBC and whether CXCR4 expression in TNBC could be a prognostic indicator. TNBCs tissues were formalin fixed, paraffin embedded and hematoxylin-eosin (H&E) stained. Immunohistochemical staining was utilized to determine the CXCR4 expression in those specimens. Statistical analyses were performed using SPSS16.0 software to reveal the correlation of CXCR4 expression in TNBC specimens and cancer recurrence and cancer-related death. Our results showed that there was a strong association between CXCR4 overexpression and both menopause and the histological cancer grade of TNBC patients (p values were separately 0.004 and 0.001). The 5-y disease-free survival (DFS) and the 5-y overall survival (OS) were 57.69% and 58.33% for the low-CXCR4 group versus 42.11% and 44.74% for the high-CXCR4 group, respectively (p＝0.031 and 0.048). CXCR4 overexpression plays an important role in triple-negative breast cancers, and may be a predictor of poor prognosis.